DX
DXCM
HealthcareDexCom, Inc.
Medical Devices
Total Trades
16
Unique Traders
4
Purchases / Sales
8/8
News Articles
5
Trading History
| Date | Politician | Asset | Action | Amount | Trade Price | 30D Price | 1M Return | Alpha | 1M Prediction |
|---|---|---|---|---|---|---|---|---|---|
Feb 17, 2026 |  Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $70.43 | $67.27 | -4.5% | -1.1% | |
Feb 5, 2026 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $69.89 | $68.10 | -2.6% | -1.8% | |
Jan 29, 2026 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $74.00 | $73.43 | -0.8% | +0.4% | |
Dec 12, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $66.96 | $67.40 | +0.7% | -1.4% | |
Dec 5, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $65.49 | $66.54 | +1.6% | +1.7% | |
Sep 29, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $66.46 | $68.18 | +2.6% | -1.0% | |
Aug 4, 2025 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $76.25 | $78.92 | +3.5% | +1.5% | |
May 28, 2025 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $86.98 | $86.33 | -0.7% | -5.7% | |
May 15, 2025 |  Rob BresnahanR | Stock | Buy | $1,001 - $15,000 | $85.67 | $81.99 | -4.3% | -5.4% | |
May 12, 2025 |  Jefferson ShreveR | Stock | Sell | $15,001 - $50,000 | $85.05 | $82.99 | -2.4% | -5.6% | |
May 8, 2025 | Jefferson ShreveR | Stock | Buy | $15,001 - $50,000 | $85.34 | $86.67 | +1.6% | -4.5% | |
Apr 23, 2025 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $66.86 | $84.51 | +26.4% | +18.2% | |
Apr 8, 2025 | Rob BresnahanR | Stock | Sell | $1,001 - $15,000 | $60.69 | $85.34 | +40.6% | +26.8% | |
Apr 7, 2025 | Jefferson ShreveR | Stock | Sell | $15,001 - $50,000 | $61.63 | $83.35 | +35.2% | +24.0% | |
Feb 25, 2025 | Rob BresnahanR | Stock | Buy | $1,001 - $15,000 | $88.32 | $69.47 | -21.3% | -17.1% | |
Dec 31, 2024 |  Kevin HernR | Stock | Sell | $50,001 - $100,000 | $77.77 | $87.62 | +12.7% | +9.4% |
Recent News
DexCom, Inc. (DXCM) Continues to Focus on Glucose Sensors Leadership
Yahoo-Invalid Date
Did DexCom's (DXCM) Strong 2025 Results and Buybacks Just Reframe Its 2026 Growth Story?
Yahoo-Invalid Date
The 5 Most Interesting Analyst Questions From DexCom’s Q4 Earnings Call
Yahoo-Invalid Date
P/E Ratio Insights for DexCom
Benzinga-Invalid Date
Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $80
Benzinga-Invalid Date